新型内路明胶支架治疗难治性青光眼12个月的有效性与安全性
单臂、开放标签、多中心临床研究评估内路明胶支架(XEN 45 Gel Stent)在难治性青光眼中的降眼压效果与安全性。65例患者植入支架,12个月时75.4%(46/61)达到眼压较基线降低≥20%且用药不变或减少,平均眼压变化-9.1 mm Hg,平均用药数从3.5降至1.7。无术中并发症或意外术后不良事件,多数不良事件为轻/中度。
要点
- 12个月时75.4%(46/61)患者眼压较基线降低≥20%且用药不变或减少。
- 平均眼压变化-9.1 mm Hg(95%CI:-10.7,-7.5),平均用药数从3.5降至1.7。
- 无术中并发症或意外术后不良事件,常见不良事件为需要针刺、非持续性视力下降和短暂低眼压。
核心结论
- 明胶支架降低眼压和用药量,未增加意外安全性问题,为难治性青光眼患者提供微创手术选择。
研究设计与样本
- 单臂、开放标签、多中心临床研究,纳入既往滤过/睫状体破坏手术失败或最大耐受药物治疗下眼压未控制且用药后眼压≥20且≤35 mm Hg、视野平均偏差≤-3 dB的患者。
- 在丝裂霉素C预处理后行内路明胶支架(XEN 45 Gel Stent)植入,共65例患者植入(意向治疗/安全性人群)。
主要发现
- 12个月时75.4%(46/61,观察数据)患者眼压较基线降低≥20%且用药不变或减少。
- 12个月时平均眼压较基线变化-9.1 mm Hg(95%CI:-10.7,-7.5)(n=52,观察数据),排除数据缺失患者(n=4)和需青光眼相关二次手术干预患者(n=9)。
- 平均用药数从基线3.5降至12个月1.7。
- 无术中并发症或意外术后不良事件报告;多数不良事件为轻/中度,常见不良事件包括需要针刺(无威胁视力并发症)、非持续性最佳矫正视力下降和短暂低眼压(无需手术干预)。
关键数值与推荐
- 主要性能结局:12个月时眼压较基线降低≥20%且用药不变或减少的患者百分比,以及平均眼压较基线变化。
- 评估手术相关并发症和眼部不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the intraocular pressure (IOP)-lowering performance and safety of an ab interno gelatin stent (XEN 45 Gel Stent, Allergan plc, Irvine, California, USA), a minimally invasive glaucoma surgery device, in refractory glaucoma. DESIGN: Single-arm, open-label, multicenter clinical study. METHODS: Following mitomycin C pretreatment, the stent was placed ab interno in patients who failed prior filtering/cilioablative procedure or had uncontrolled IOP on maximum-tolerated medical therapy, with medicated IOP ≥20 and ≤35 mm Hg and visual field mean deviation ≤-3 dB. Primary performance outcomes: patients (%) achieving ≥20% IOP reduction from baseline on the same or fewer medications and mean IOP change from baseline at month 12. Procedure-related complications and ocular adverse events (AEs) were assessed. RESULTS: Sixty-five patients were implanted (intent-to-treat/safety population). At 12 months, 75.4% (46/61; observed data) reported ≥20% IOP lowering from baseline on the same or fewer medications. Mean IOP change from baseline was -9.1 mm Hg (95% confidence interval [CI]: -10.7, -7.5) (n = 52; observed data) at 12 months, excluding patients with missing data (n = 4) and those requiring a glaucoma-related secondary surgical intervention (n = 9). Mean medication count decreased from 3.5 (baseline) to 1.7 (12 months). No intraoperative complications or unexpected postoperative AEs were reported. Most AEs were mild/moderate; common AEs included needling (without sight-threatening complications), nonpersistent loss of best-corrected visual acuity, and transient hypotony (requiring no surgical intervention). CONCLUSIONS: The gelatin stent reduced IOP and medication use without raising unexpected safety concerns, offering a minimally invasive surgical option for refractory glaucoma patients.
引用
- Grover DS, Flynn WJ, Bashford KP, et al. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. Am J Ophthalmol. 2017. PMID: 28784554. doi:10.1016/j.ajo.2017.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。